Product Description
Carnitine, derived from an amino acid, is found in nearly all cells of the body. Its name is derived from the Latin carnus or flesh, as the compound was isolated from meat. Carnitine is the generic term for a number of compounds that include L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine (Sourced from: https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/)
Mechanisms of Action: CPT1 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Chile | Colombia | Dominican Republic | Ecuador | Egypt | France | Hong Kong | India | Italy | Korea | Malaysia | Malta | Mexico | Pakistan | Peru | Philippines | Russia | Spain | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Iperboreal Pharma Srl
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RELIEF (Researching the Effectiveness of a nutraceuticaL Intervention for multiplE sclerosis-related Fatigue) | P2 |
Completed |
Multiple Sclerosis |
2023-01-05 |